Ingalls & Snyder LLC’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-1,574
Closed -$208K 460
2024
Q4
$208K Sell
1,574
-25
-2% -$3.52K 0.01% 406
2024
Q3
$233K Buy
+1,599
New +$231K 0.01% 397
2023
Q4
Sell
-2,530
Closed -$309K 454
2023
Q3
$309K Sell
2,530
-10
-0.4% -$1.27K 0.01% 338
2023
Q2
$322K Sell
2,540
-29
-1% -$3.77K 0.02% 343
2023
Q1
$332K Hold
2,569
0.02% 329
2022
Q4
$337K Sell
2,569
-15
-0.6% -$1.94K 0.02% 329
2022
Q3
$302K Hold
2,584
0.02% 337
2022
Q2
$304K Sell
2,584
-100
-4% -$11.9K 0.02% 344
2022
Q1
$350K Sell
2,684
-225
-8% -$29.3K 0.02% 344
2021
Q4
$444K Sell
2,909
-286
-9% -$44.3K 0.02% 329
2021
Q3
$517K Sell
3,195
-55
-2% -$9.26K 0.02% 304
2021
Q2
$532K Buy
3,250
+285
+10% +$43.9K 0.02% 306
2021
Q1
$446K Sell
2,965
-566
-16% -$89.9K 0.02% 309
2020
Q4
$535K Sell
3,531
-2,309
-40% -$330K 0.03% 277
2020
Q3
$791K Buy
5,840
+340
+6% +$46.1K 0.05% 202
2020
Q2
$752K Buy
5,500
+283
+5% +$36.1K 0.04% 221
2020
Q1
$562K Sell
5,217
-379
-7% -$43.6K 0.04% 251
2019
Q4
$674K Sell
5,596
-253
-4% -$28.2K 0.04% 239
2019
Q3
$582K Sell
5,849
-3,051
-34% -$319K 0.03% 271
2019
Q2
$971K Sell
8,900
-40
-0.4% -$4.25K 0.05% 227
2019
Q1
$999K Sell
8,940
-4,167
-32% -$457K 0.05% 219
2018
Q4
$1.26M Sell
13,107
-1,245
-9% -$132K 0.07% 186
2018
Q3
$1.75M Sell
14,352
-145
-1% -$17.1K 0.07% 181
2018
Q2
$1.59M Buy
14,497
+1,933
+15% +$207K 0.07% 168
2018
Q1
$1.34M Sell
12,564
-654
-5% -$72.5K 0.07% 180
2017
Q4
$1.41M Buy
13,218
+1,347
+11% +$144K 0.06% 181
2017
Q3
$1.32M Sell
11,871
-924
-7% -$98.8K 0.07% 167
2017
Q2
$1.32M Buy
12,795
+6,414
+101% +$632K 0.07% 167
2017
Q1
$624K Sell
6,381
-483
-7% -$46.2K 0.03% 238
2016
Q4
$607K Buy
6,864
+1,701
+33% +$155K 0.03% 238
2016
Q3
$498K Buy
5,163
+150
+3% +$14.3K 0.03% 250
2016
Q2
$430K Buy
+5,013
New +$450K 0.03% 272

Other funds holding IBB

Ingalls & Snyder LLC's IBB Position: Q1 2025 in Review

Ingalls & Snyder LLC sold out of iShares Biotechnology ETF (IBB) in Q1 2025, closing a stake of 1,574 shares — an estimated $208K sold.

Ingalls & Snyder LLC first reported a position in IBB in Q2 2016 and held it in 32 quarters. The position peaked at $1.75M in Q3 2018. 831 funds tracked by Wall St. Rank hold IBB as of Q1 2025.

  • Ingalls & Snyder LLC reported no remaining iShares Biotechnology ETF position as of Q1 2025 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 1,574 iShares Biotechnology ETF shares in Q1 2025, an estimated $208K.
  • Ingalls & Snyder LLC first reported a position in iShares Biotechnology ETF in Q2 2016 and held it in 32 quarters.
  • Ingalls & Snyder LLC's iShares Biotechnology ETF position peaked at $1.75M in Q3 2018.
  • 831 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2025.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2025, filed 12 May 2025.